Business
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\nEloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases\nCompany Transfers Headquarters to Boston, MA\nPR Newswire\nSAN DIEGO and BOSTON, Sept. 8, 2017\n\n\n\nSAN DIEGO and BOSTON, Sept. 8, 2017 /PRNewswire/ -- Sevion Therapeutics, Inc. (OTCQB: SVON) and Eloxx Pharmaceuticals Ltd., a clinical stage biopharmaceutical company developing therapeutics for genetic diseases caused by nonsense mutations, today announced the expansion of its development team with the appointments of Colin Scott, M.D., as Medical Director who will report directly to Pedro Huertas, M.D., Ph.D., the Company's Chief Medical Officer; and Neal Sharpe, M.D., as Senior Director of Toxicology. In addition, the Company is announcing that it has transferred its operations headquarters from Rehovot, Israel to Boston, Massachusetts, USA. \n\n\"Colin and Neal together with Pedro will play a key role as we continue to advance our lead drug candidate, ELX-02, to treat a wide variety of rare genetic diseases,\" said Dr. Silvia Noiman, CEO and co-founder of Eloxx. \"This team has an exemplary track record in leading comprehensive preclinical and clinical development programs, medical affairs and supporting regulatory submissions globally. We are also pleased to transfer our business headquarters to the Boston area, an important hub for biopharmaceutical innovation. We look forward to the continued build-out of our senior leadership team and executing on our business objectives throughout 2017 and beyond.\" \n\nPedro Huertas, M.D., Ph.D., as Chief Medical Officer\n\nDr. Huertas brings over 20 years of pharmaceutical industry experience in research and development, medical affairs, and regulatory affairs concerning therapeutics for human genetic and metabolic diseases. Dr. Huertas has extensive experience dealing with a...